| Literature DB >> 27177089 |
Juntao Ke1,2, Jiao Lou1,2, Xueqin Chen1,2, Jiaoyuan Li1,2, Cheng Liu1,2, Yajie Gong1,2, Yang Yang1,2, Ying Zhu1,2, Yi Zhang1,2, Jianbo Tian1,2, Jiang Chang1, Rong Zhong1,2, Jing Gong1,2, Xiaoping Miao1,2.
Abstract
Genome-wide association studies (GWASs) have established chromosome 5q31.1 as a risk locus for colorectal cancer (CRC). We previously identified a potentially regulatory single nucleotide polymorphism (SNP) rs17716310 within 5q31.1. Now, we extended our study with another independent Chinese population, functional assays and analyses of TCGA (The Cancer Genome Atlas) data. Significant associations between rs17716310 and CRC risk were found in Present Study including 1075 CRC cases and 1999 controls (additive model: OR = 1.149, 95% CI = 1.027-1.286, P = 0.016), and in Combined Study including 1766 cases and 2708 controls (additive model: OR = 1.145, 95% CI = 1.045-1.254, P = 0.004). Dual luciferase reporter gene assays indicated that the variant C allele obviously increased transcriptional activity. Using TCGA datasets, we indicated rs17716310 as a cis expression quantitative trait locus (eQTL) for the gene SMAD5, whose expression was significantly higher in CRC tissues. These findings suggested that the functional polymorphism rs17716310 A > C might be a genetic modifier for CRC, promoting the expression of SMAD5 that belonged to the transforming growth factor beta (TGF-β) signaling pathway.Entities:
Keywords: a functional variant; chromosome 5q31.1; colorectal cancer; rs17716310
Mesh:
Year: 2016 PMID: 27177089 PMCID: PMC5085221 DOI: 10.18632/oncotarget.9298
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
The characteristics of the study population
| Present Study | Combined Study | |||||||
|---|---|---|---|---|---|---|---|---|
| Case (%) | Control (%) | χ2 | Case (%) | Control (%) | χ2 | |||
| Total | 1075 | 1999 | 1766 | 2708 | ||||
| Gender | 0.707 | 0.400 | 0.892 | 0.345 | ||||
| Male | 646 (60.1) | 1170 (58.5) | 1049 (59.4) | 1570 (58.0) | ||||
| Female | 429 (39.9) | 829 (41.5) | 717 (40.6) | 1138 (42.0) | ||||
| Age (mean ± SD) | 60.51 ± 12.82 | 61.07 ± 11.97 | 0.232 | 60.36 ± 12.62 | 60.79 ± 12.30 | 0.254 | ||
| Agegroup | 3.959 | 0.266 | 0.718 | 0.869 | ||||
| ≤ 50 | 237 (22.1) | 460 (23.0) | 386 (21.9) | 614 (22.7) | ||||
| 51–60 | 281 (26.1) | 574 (28.7) | 487 (27.6) | 755 (27.9) | ||||
| 61–70 | 293 (27.3) | 494 (24.7) | 475 (26.9) | 703 (26.0) | ||||
| ≥ 71 | 263 (24.5) | 471 (23.6) | 417 (23.6) | 636 (23.5) | ||||
| Smoking Status | 10.990 | 12.723 | ||||||
| Non-Smoker | 639 (59.4) | 1309 (65.5) | 1087 (61.6) | 1808 (66.8) | ||||
| Smoker | 436 (40.6) | 690 (34.5) | 679 (38.4) | 900 (33.2) | ||||
Abbreviations: SD, standard deviation.
P value was calculated by chi-square test.
P value was calculated by the t test.
The nominal significant results were in bold.
Association between individual SNP and colorectal cancer risk
| Present Study | Combined Study | |||||||
|---|---|---|---|---|---|---|---|---|
| Cases (%) | Controls (%) | OR (95% CI) | Cases (%) | Control (%)s | OR (95% CI) | |||
| AA | 481 (45.2) | 951 (48.1) | 1.000 | 775 (44.4) | 1289 (48.2) | 1.000 | ||
| AC | 454 (42.7) | 842 (42.6) | 1.071 (0.914–1.256) | 0.397 | 768 (44.0) | 1126 (42.1) | ||
| CC | 129 (12.1) | 183 (9.3) | 203 (11.6) | 259 (9.7) | ||||
| Dominant | 1.133 (0.975–1.316) | 0.104 | ||||||
| Recessive | ||||||||
| Additive | ||||||||
Abbreviations: OR, Odds ratio; 95% CI, 95% confidence interval.
Data were calculated by logistic regression model after adjusting for sex, age group and smoking status.
The nominal significant results were in bold.
Interaction analysis between smoking and rs17716310 associated with CRC risk in combined study
| Smoking Status | Genotype | Case/Control | OR (95% CI) | ||
|---|---|---|---|---|---|
| Non-smoker | AA | 470/856 | 1.000 | 0.509 | |
| AC + CC | 601/925 | 1.186 (1.019–1.382) | |||
| Smoker | AA | 304/432 | 1.363 (1.114–1.669) | ||
| AC + CC | 369/460 | 1.560 (1.281–1.898) |
Pmult was calculated using the multiplicative interaction term.
Padd was calculated using the additive interaction model.
Data were calculated by logistic regression model after adjusting for gender and age group.
The nominal significant results were in bold.
Figure 1Reporter gene assays with two constructs containing major and minor alleles of rs17716310 in HCT116 and LoVo
Both constructs were cotransfected with pRL-SV40 to standardize transfection efficiency. Luciferase levels of pGL3-promoter and pRL-SV40 were determined in triplicate. Data shown are the from three independent transfection experiments, each performed in triplicate. The rs17716310 C-containing enhancer drove significantly higher reporter gene expression than the rs17716310 A-containing fragment in both CRC cell lines (**P < 0.01).
Expression correlation between rs17716310 and flanking 1 Mb genes
| Gene | Correlation | Correlation R2 |
|---|---|---|
| 1.311E–01 | 9.020E–03 | |
| 1.371E–01 | 8.749E–03 | |
| 1.426E–01 | 8.510E–03 | |
| 1.694E–01 | 7.478E–03 | |
| 2.307E–01 | 5.695E–03 | |
| 3.019E–01 | 4.229E–03 | |
| 3.151E–01 | 4.004E–03 | |
| 3.281E–01 | 3.796E–03 | |
| 4.023E–01 | 2.786E–03 | |
| 4.380E–01 | 2.388E–03 | |
| 4.524E–01 | 2.242E–03 | |
| 5.204E–01 | 1.641E–03 | |
| 5.212E–01 | 1.635E–03 | |
| 5.324E–01 | 1.549E–03 | |
| 6.699E–01 | 7.222E–04 | |
| 8.198E–01 | 2.064E–04 | |
| 8.438E–01 | 1.543E–04 | |
| 8.716E–01 | 1.039E–04 | |
| 8.742E–01 | 9.965E–05 | |
| 9.262E–01 | 3.409E–05 | |
| 9.610E–01 | 9.483E–06 | |
| 9.949E–01 | 1.604E–07 |
The nominal significant results were in bold.
Figure 2Expression correlation between rs17716310 and SMAD5
The C allele of rs17716310 was correlated with higher SMAD5 expression under an adjusted linear regression model (P < 0.05). The values (average ± SD) of expression level (log2) were 10.29 ± 0.42 for CC, 10.28 ± 0.46 for CA and 10.06 ± 0.54 for AA.